AZNCIK 901832

ASTRAZENECA PLC

EDGAR filings

Customers

1 federal agency

Suppliers

1 disclosed

Federal obligations

$12.1M

FY2023 · USAspending.gov

Latest period

Dec 31, 2025

10-K filed 2026-03-13

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 3

Companies that disclose AZN as a major customer, as a share of their own revenue. 1 active, 2 lapsed.

Company	% of their revenue	Est. $ from AZN	Period	Trend	Status	Source
INO INOVIO PHARMACEUTICALS, INC.	2%	$35.5K	FY 2021-12-31	±0.0pp	Lapsed Last seen 2021-12-31	10-K 2022-03-01
AstraZeneca $ 41,659 2 % $ 170,587 2 % $ 3,194,877 78 % 10-K filed 2022-03-01 Period FY 2021-01-01 to 2021-12-31 (2%), FY 2020-01-01 to 2020-12-31 (2%)Accession 0001055726-22-000008 During the year ended December 31, 2019, we derived 78% of our revenue from AstraZeneca. 10-K filed 2022-03-01 Period FY 2019-01-01 to 2019-12-31 (78%)Accession 0001055726-22-000008 During the year ended December 31, 2018, we derived 75% of our revenue from ApolloBio and 23% of our revenue from AstraZeneca. 10-K filed 2021-03-01 Period FY 2018-01-01 to 2018-12-31 (23%)Accession 0001055726-21-000018
ARRAY BIOPHARMA INC ARRAY BIOPHARMA INC	0.2%	$15.5K	3M 2014-03-31	−35.7pp	Lapsed Last seen 2014-03-31	10-Q 2014-05-09
AstraZeneca AB 0.2 % 0.2 % 14.1 % 0.4 % 10-Q filed 2014-05-09 Period 3M 2014-01-01 to 2014-03-31 (0.2%), 3M 2013-01-01 to 2013-03-31 (0.2%)Accession 0001100412-14-000026 AstraZeneca AB 35.9 % — % 17.9 % — % 10-Q filed 2014-02-05 Period 3M 2013-10-01 to 2013-12-31 (35.9%)Accession 0001100412-14-000010
NKTR NEKTAR THERAPEUTICS	Named	—	FY 2025-12-31	—	Active	10-K 2026-03-13
Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45%, 37%, and 14% of our revenue, respectively, for the year ended December 31, 2025. 10-K filed 2026-03-13 Period FY 2025-01-01 to 2025-12-31Accession 0001193125-26-104547 Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39%, 18%, 17%, 12% and 10% of our revenue, respectively, for the year ended December 31, 2024. 10-K filed 2026-03-13 Period FY 2024-01-01 to 2024-12-31Accession 0001193125-26-104547

Federal contracts 1

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $12.1M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Health and Human Services Centers for Disease Control and Prevention	$12.1M	FY 2023	3		75D30123D15809
PEDIATRIC FLU VACCINES 2023-2024 Award 75D30123D15809 on USAspending.gov ↗ Largest of 3 awards in FY2023: $12.0M obligated

Alerts are coming

Get an email when AZN's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.